Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Net Income: 2016-2025

Historic Net Income for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to -$52.0 million.

  • Rocket Pharmaceuticals' Net Income rose 24.15% to -$52.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$248.2 million, marking a year-over-year increase of 7.45%. This contributed to the annual value of -$266.8 million for FY2024, which is 4.13% down from last year.
  • Per Rocket Pharmaceuticals' latest filing, its Net Income stood at -$52.0 million for Q3 2025, which was up 26.89% from -$71.1 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' Net Income's 5-year high stood at -$33.8 million during Q2 2021, with a 5-year trough of -$71.9 million in Q2 2024.
  • For the 3-year period, Rocket Pharmaceuticals' Net Income averaged around -$64.5 million, with its median value being -$64.2 million (2023).
  • The largest annual percentage gain for Rocket Pharmaceuticals' Net Income in the last 5 years was 27.53% (2021), contrasted with its biggest fall of 71.22% (2021).
  • Quarterly analysis of 5 years shows Rocket Pharmaceuticals' Net Income stood at -$43.9 million in 2021, then tumbled by 55.43% to -$68.3 million in 2022, then rose by 7.86% to -$62.9 million in 2023, then increased by 2.20% to -$61.5 million in 2024, then grew by 24.15% to -$52.0 million in 2025.
  • Its Net Income stands at -$52.0 million for Q3 2025, versus -$71.1 million for Q2 2025 and -$63.5 million for Q1 2025.